KRAS & NRAS Mutation Analysis Panel in UAE | 2,500 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival FFPE blocks.
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Mandatory: NGS Test Requisition Form (Form 40) must be duly completed.

Test Overview & Methodology

The KRAS & NRAS Mutation Analysis Panel detects clinically actionable somatic mutations in the KRAS and NRAS oncogenes from formalin-fixed paraffin-embedded (FFPE) tumor tissue. This advanced molecular profiling supports oncologists in personalizing targeted therapy for colorectal, lung, pancreatic, and other solid tumors, ensuring patients in the UAE receive guideline-compliant care.

Feature	Our Test (KRAS & NRAS Panel)	Closest Alternative (Limited PCR Panel)
Methodology	PCR, Fragment Analysis & DNA Sequencing	Real‑Time PCR only (hotspot restricted)
Mutations Covered	Comprehensive exonic coverage (30+ actionable variants)	5–10 common hot-spot mutations
Turnaround Time	Sample Tue by 11 am; Report Mon (under 7 days)	10–14 working days
Diagnostic Sensitivity	99.9% (LC-MS/MS cross‑validated)	~90%
Clinical Utility Standard	DHA/MOHAP Guidelines; ISO 9001:2015	Generic lab SOPs

Physician Insight & Safety Protocols

“As a diagnostic radiology specialist, I understand how overwhelming a cancer diagnosis can be. This KRAS and NRAS mutation analysis is a vital step in guiding your personalized treatment, but it must always be correlated with your complete clinical history, imaging, and pathology. Please review every result with your treating oncologist—never make treatment decisions based on a single laboratory report.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Medication Advisory

⚠️ Do not discontinue any prescribed medication without consulting your doctor. This test provides molecular information that complements—not replaces—your clinical treatment plan.

Exclusion Criteria & Emergency Red Flags

Exclusion: FFPE block with less than 10% tumor content; unlabeled or improperly fixed tissue; missing or incomplete NGS Test Requisition Form (Form 40).
Exclusion: Sample received after Tuesday 11 am cut-off without prior approval.
Red Flag: If you experience new or worsening symptoms (severe pain, bleeding, shortness of breath, high fever), seek emergency care immediately—do not wait for test results.
Red Flag: Test results indicating a resistant mutation must be urgently discussed with your oncologist; do not self-adjust chemotherapy or biologic agents.

Patient FAQ & Clinical Guidance

1. What exactly does the KRAS & NRAS Mutation Analysis Panel detect?

This panel identifies somatic mutations in the KRAS and NRAS genes that predict response or resistance to anti-EGFR targeted therapies in cancers such as colorectal, lung, and pancreatic tumours. It uses high-resolution PCR, fragment analysis and DNA sequencing to detect clinically actionable variants, enabling your oncologist to select the most effective treatment.

2. How is the test performed and what sample do I need?

A small portion of your previously collected tumour tissue (formalin-fixed paraffin-embedded block) is required, ensuring at least 10% tumour content. The sample must reach our central lab by Tuesday 11 am for a Monday report. Our secure courier service retrieves the block directly from your hospital or pathology archive.

3. What do the results mean for my cancer treatment?

Results categorise mutations as 'wild-type' (no mutation) or specific variants such as G12D or G13D, which directly influence anti-EGFR drug eligibility. A wild-type result usually indicates that cetuximab or panitumumab may be effective, while many mutations confer resistance. Your oncologist will combine these findings with your complete clinical picture to finalise your treatment protocol.

UAE Regulatory & Data Privacy Adherence

Your health data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All test results are encrypted, stored securely, and shared only with your treating physician and authorised healthcare providers. No data is shared with third parties without your explicit consent.

Clinical & Logistical Metadata

Test Name	KRAS & NRAS Mutation Analysis Panel
Price (AED)	2,500
Turnaround Time	7 working days (sample Tue by 11 am, report Mon)
Sample Type / Matrix	Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue – Archival Specimen
Methodology Used	PCR, Fragment Analysis & DNA Sequencing
ICD-10-CM Code	C18.9, C20, C34.9, C25.9
LOINC Code	91848-0, 91849-8
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE